Slashing the Costs of New Drug Discovery

Sistemic Ltd, the recent winners of the coveted Most Promising Life Science Company by Nexxus, announced the launch of their SistemTOX™ early predictive and investigative drug toxicity screening service. Based on world-leading Scottish microRNA research and technology, SistemTOX™ filters out potentially harmful compounds early in the development process, helping to save millions of pounds in costs.

The launch of SistemTOX™ comes at a time when the industry has been experiencing huge issues with compound toxicity. Sistemic CEO Professor Chris Hillier, stated: “Building on leading Scottish research expertise, SistemTOX™ uses microRNA profiling to decipher, early on, potential toxicity. Furthermore, it is not just a yes/no answer - it also provides context which feeds important information quickly back to the scientists. Basically it places the power back into the developer’s hands and reduces risk.” SistemTOX™ has already been extensively evaluated with selected partners and is another exciting development from one of Scotland’s fastest growing life science companies.